Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sinopharm Group Co ( (HK:1099) ) just unveiled an announcement.
Sinopharm subsidiary China National Accord Medicines reported first-quarter 2026 revenue of RMB 17.82 billion, down 2.57% year on year, reflecting modest top-line pressure in its pharmaceutical distribution business. Net profit attributable to shareholders fell 12.36% to RMB 287 million, with basic earnings per share declining to RMB 0.52 and return on equity easing to 1.53%.
Despite weaker earnings and a sharper drop in operating cash flow, total assets were broadly stable at about RMB 49.12 billion and equity attributable to shareholders edged up 1.54% to RMB 18.90 billion. The figures suggest Sinopharm Accord is facing margin and cash flow headwinds even as its balance sheet remains solid, a mixed signal for investors watching profitability in China’s pharma distribution sector.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$22.50 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
More about Sinopharm Group Co
Sinopharm Group Co. is a major Chinese pharmaceutical conglomerate with subsidiaries listed on mainland exchanges, including China National Accord Medicines Corporation Ltd. Sinopharm Accord focuses on the distribution and sale of medicines and related healthcare products within China’s pharmaceutical market.
Average Trading Volume: 5,853,356
Technical Sentiment Signal: Sell
Current Market Cap: HK$57.7B
For an in-depth examination of 1099 stock, go to TipRanks’ Overview page.